Drug profile · INN
dengue tetravalent vaccine (live, attenuated)
QDENGA
dengue tetravalent vaccine (live, attenuated) (QDENGA) is a biological vaccine - induces immune response. Associated with Takeda.
EMA: approved Antiinfectives for systemic use (J07) J07BX04
Patents linked 3
Pipeline programs 17
News articles 0
Drug details — dengue tetravalent vaccine (live, attenuated)
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 3
- Programs
- 17
- Data quality
- 0.89
Quick answer
dengue tetravalent vaccine (live, attenuated) (QDENGA) is a biological vaccine - induces immune response. Associated with Takeda.
Key facts
INN dengue tetravalent vaccine (live, attenuated)
Brand QDENGA
Mechanism Biological vaccine - induces immune response
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BX04
Originator Takeda
Mechanism of action
Biological vaccine - induces immune response
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is dengue tetravalent vaccine (live, attenuated)?
dengue tetravalent vaccine (live, attenuated) (QDENGA) is a biological vaccine - induces immune response. Associated with Takeda.
What is the brand name for dengue tetravalent vaccine (live, attenuated)?
QDENGA is a marketed brand name for dengue tetravalent vaccine (live, attenuated). Check FDA Drugs@FDA for the current US label holder and prescribing information.